Newly unveiled startup Morphic Therapeutic hopes that it’s solved some of the technical challenges that have hindered integrin-targeting therapeutics. It’s got more insight into their mechanism of action--as well as a novel structural approach that could enable a small molecule, oral version of what has previously only been injectable biologics.
Image: http://www.fiercebiotech.com
